Advertisement

Tijdschrift voor Ouderengeneeskunde

, Volume 35, Issue 4, pp 153–157 | Cite as

Evidence-based case report: Orale antistolling bij oudere patiënten en het risico op intracraniële bloedingen

  • M. Grammata
  • S. Visser
  • M. C. A Smit
Praktijkartikel
  • 40 Downloads

Samenvatting

Een 85-jarige man is opgenomen op de psychogeriatrische afdeling van een verpleeghuis vanwege M. Alzheimer. Sinds zes weken is zijn situatie achteruit gegaan. Patiënt is minder mobiel en de communicatie is verslechterd, patiënt praat onduidelijker dan voorheen. Bij lichamelijk onderzoek wordt een lichte dysartrie en krachtsverlies van het rechter been waargenomen. Er zijn geen aanwijzingen voor een delier. Patiënt gebruikt orale antistolling (acenocoumarol) in verband met chronisch nietvalvulair atriumfibrilleren. Tevens heeft patiënt hypertensie in de voorgeschiedenis. Het beleid is terughoudend, onder andere is afgesproken om ziekenhuisopnamen te voorkomen.

Literatuur

  1. 1.
    Gull⊘v AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation. The AFASAK 2 study. Arch Intern Med 1999; 159: 1322-1328.Google Scholar
  2. 2.
    Mant J, Hobbs R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomized controlled trial. Lancet 2007; 370: 493-503.Google Scholar
  3. 3.
    Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label, non-inferiority trial. Lancet 2008; 371:315-321.Google Scholar
  4. 4.
    Go AS, Hylek EM, Philips KA, et al. Prevalence of atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the Anticoagulation and Risk factors in Atrial Fibrillation (ATRIA) study. JAMA 2001; 285: 2370.Google Scholar
  5. 5.
    Heeringa J, Kuip DA van der, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949.Google Scholar
  6. 6.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-988.Google Scholar
  7. 7.
    Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 14491457.Google Scholar
  8. 8.
    Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.Google Scholar
  9. 9.Fang
    MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004; 141: 745-752.Google Scholar
  10. 10.
    Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task force on practice guidelines and the European society of cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation): developed in collaboration with the North American society of pacing and electrophysiology. J Am Coll Cardiol 2001; 38: 12311266.Google Scholar
  11. 11.
    Landefeld CS, Goldman L, Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989; 87: 144-152.Google Scholar
  12. 12.
    Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med. 1989; 87: 153-159.Google Scholar
  13. 13.
    EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993; 342: 1255-1262.Google Scholar
  14. 14.
    Palareti G, Leali N, Cocceri S, et al. on behalf of the study on complications of oral anticoagulant therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective study (SCOAT). Lancet. 1996; 348: 423-428.Google Scholar
  15. 15.
    Dunn M, Blackburn T. anticoagulant treatment of atrial fibrillation in the elderly. Postgrad Med J 1992; 68(suppl 1): §57-§60.Google Scholar
  16. 16.
    Gurwitz JH, Goldberg RJ, Holden A, et al. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med. 1988;148: 1733-1736.Google Scholar
  17. 17.
    Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996; 124:970-979.Google Scholar
  18. 18.
    Gitter MJ, Jaeger TM, Petterson TM, et al. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995; 70: 725-733.Google Scholar

Copyright information

© Bohn Stafleu van Loghum 2010

Authors and Affiliations

  1. 1.

Personalised recommendations